Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

MDXX-class molecules producer PharmAla Biotech Holdings Inc. and natural psychedelics developer Filament Health Corp's FLHLF partnership is seeing the release of GMP-compliant MDMA capsules for distribution to clinical trials and authorized patients in Canada and worldwide.

PharmAla CEO Nick Kadysh says the company has been working for some time to fill the MDMA backlog for clinical researchers at a global scale. 

“As the psychedelics industry matures, the amount of clinical research for MDMA is set to grow,” Kadysh noted. Adding that PharmAla is now focused on jurisdictions like Australia, “which will require full commercial-scale manufacturing of both GMP API and drug product to fulfill demand for patients,” and other jurisdictions still to come. Learn more HERE.

LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

Psychedelics biopharma company Mind Medicine Inc. MNMD shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discovery of LSD by Swiss doctor Albert Hofmann.

The double-blind Phase 2 study led by MindMed’s collaborators at University Hospital Basel (UHB) and the University Hospital of Psychiatry, Matthias Liechti and Felix Mueller, demonstrated “significant, rapid, durable and beneficial effects” on the mitigation of MDD symptoms.

MindMed holds exclusive access and rights to the data generated by the studies within the partnership.

Learn more HERE.

More Treatment Locations, Network Resources And Licensing Offers

Ketamine clinics operator Revitalist Lifestyle & Wellness Ltd. RVLWF and psilocybin bioscience and wellness platforms company Wake Network have partnered with GCM Partners LLC to offer new ketamine treatment locations in two facilities in Chicago, two in Orlando and one in Miami, potentially expanding therapy for over 50,000 people.

TARA Mind is the new platform providing mainstream access to psychedelic treatments, founded by military veteran and former Navy Seal Marcus Capone in partnership with Grant Verstandig, CEO of $3 million seed funding financer VC Red Cell Partners.

Meanwhile, California’s Humboldt County is seeing a new offer for an immersive ketamine-assisted therapy retreat, and mental healthcare company Numinus Wellness Inc. NUMIF has launched its clinic licensing model providing independent practitioners the chance to own and operate their own clinic under the Numinus brand through a licensing and services deal.

The Milestone Round

Each week, Benzinga learns about new clinical trials, compounds and potential treatments:

• Psilocybin-assisted therapy showed positive for cancer patients suffering from major depression in a Phase 2 clinical trial

• Atai ATAI has dosed its first subject on an IV-to-subcutaneous bridging study testing proprietary R-ketamine

• Cybin CYBN is now offering a free, online training for psychedelic therapy facilitators

• Numinus Wellness reported on its solid performance on Q2 2023

• FSD Pharma HUGE announced the spinout of an upcoming subsidiary

• Awakn Life Sciences AWKNF has seen changes in leadership and stock ownership.

• Find out the latest on states’ reform bills this week

• Check out BZ’s interview series discussing decolonization and internalized oppression in the psychedelics space

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance April 10-14:

AdvisorShares Psychedelics ETF PSIL opened Monday, April 10, at $1.78, slightly below prior week’s opening at $1.83.

After a weekly ascending trend with highest achieved at $1.83 on Thursday 13, the stock closed at $1.80 on Friday, April 14, slightly up considering closing price of $1.78 on Thursday 6 yet still lower than two-weeks’ past closing at $1.87.

For this ETF, the yearly price range is set between $4.35 and $1.70.

Benzinga’s Psychedelics Capital Conference 2023

Missed our Psychedelics Capital Conference? Here's some EXCLUSIVE coverage from the event’s second edition:

• Investing In The Unique Growth Market Of Psychedelics

• Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'

• Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga's Psychedelics Capital Conference

• In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

• Making The World A Better Place, How Psychedelics Are Helping